BCAB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bioatla Inc (BCAB) is not a good buy for a beginner investor with a long-term strategy. The company's financials are weak, with no revenue and a history of losses, and there are no positive catalysts or strong trading signals to support a buy decision. The technical analysis indicates a bearish trend, and hedge funds are aggressively selling. Given the lack of growth prospects and negative sentiment, this stock is not suitable for the user's investment profile.
The MACD is slightly positive and expanding, indicating mild bullish momentum, but the RSI is neutral at 53.277. The moving averages are bearish (SMA_200 > SMA_20 > SMA_5), and the stock is trading below key resistance levels. The overall technical trend is bearish.
NULL. No recent news, no congress trading data, and no significant insider activity.
Hedge funds are aggressively selling, with a 760.39% increase in selling activity over the last quarter. The company's financials show no revenue and consistent losses. The stock has a high chance of minor declines in the short term (-0.38% in the next day).
In Q3 2025, revenue dropped to $0 (-100% YoY), gross margin fell to 0 (-100% YoY), and net income improved slightly to -$15.78M (+49.05% YoY). EPS also improved to -0.27 (+22.73% YoY), but the company remains unprofitable with no clear growth trajectory.
No recent analyst ratings or price target changes available for BCAB.
